Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Distillery Therapeutics

Inhibiting FABP5 for hepatocellular carcinoma

BioCentury | Mar 17, 2020
Product Development

Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal

Eureka is moving its TCR-mimicking antibodies forward with a new partner and new funding
BioCentury | Aug 22, 2019
Emerging Company Profile

Tscan: Tracking down novel T cell targets

Tscan is finding novel TCR-antigen pairs with its peptidome screening platform
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

How mosaic antigen expression makes solid tumors hard nuts to crack
BioCentury | Jun 7, 2018
Clinical News

Exact HCC assay significantly better than SOC

BioCentury | Jun 6, 2018
Product Development

Second (Ex)act

Why Exact Sciences expects smooth reimbursement path for its HCC test
Items per page:
1 - 10 of 65